Ravulizumab-cwvz

{
  "id": "MLC-T-ONC-016374",
  "term": "Ravulizumab-cwvz",
  "field": "Oncology and biomedicine",
  "definition": "A longer-acting antibody directed against terminal complement protein C5, with potential anti-inflammatory activity. Upon administration, ravulizumab-cwvz binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and preventing the complement-mediated destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). Compared to other anti-C5 antibodies, ALXN1210 is longer-acting and allows for monthly dosing. C5, a complement pathway protein, is expressed at high levels by the liver.",
  "synonyms": [
    "complement C5 inhibitor ALXN1210"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ravulizumab-cwvz/"
}